H Preibsch1, L Wanner2, S D Bahrs2, B M Wietek2, K C Siegmann-Luz3, E Oberlecher4, M Hahn4, A Staebler5, K Nikolaou2, B Wiesinger2. 1. Diagnostic and Interventional Radiology, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany. heike.preibsch@med.uni-tuebingen.de. 2. Diagnostic and Interventional Radiology, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany. 3. Diagnostic Center for Breast Cancer and Screening Mammography Brandenburg Ost, Koepenicker Straße 29, 15711, Koenigs Wusterhausen, Germany. 4. Department of Gynecology and Obstetrics, University Hospital Tuebingen, Calwerstr. 7, 72076, Tuebingen, Germany. 5. Institute of Pathology and Neuropathology, University Hospital Tuebingen, Liebermeisterstr. 8, 72076, Tuebingen, Germany.
Abstract
OBJECTIVES: To correlate the decrease in background parenchymal enhancement (BPE) and tumour response measured with MRI in breast cancer patients treated with neoadjuvant chemotherapy (NAC). METHODS: One hundred and forty-six MRI examinations of 73 patients with 80 biopsy-proven breast cancers who underwent breast MRI before and after NAC were retrospectively analysed. All images were reviewed by two blinded readers, who classified BPE into categories (BEC; 1 = minimal, 2 = mild, 3 = moderate, 4 = marked) before and after NAC. Histopathological and morphological tumour responses were analysed and compared. RESULTS: The distribution of BEC 1/2/3/4 was 25/46/18/11 % before and 78/20/2/0 % after NAC. On average, BPE decreased by 0.87 BEC. Cohen's kappa showed substantial agreement (k = 0.73-0.77) before and moderate agreement (k = 0.43-0.60) after NAC and moderate agreement (k = 0.62-0.60) concerning the change in BEC. Correlating the change in BPE with tumour response, the average decrease in BEC was 1.3 in cases of complete remission, 0.83 in cases with partial response, 0.85 in cases with stable disease and 0.40 in cases with progressive disease. Correlation analysis showed a significant correlation between the decrease in BEC and tumour response (r = -0.24, p = 0.03). CONCLUSIONS: BPE decreased by, on average, 0.87 BEC following NAC for breast cancer. The degree of BPE reduction seemed to correlate with tumour response. KEY POINTS: • BPE decreases by an average of 0.87 categories under neoadjuvant chemotherapy. • The reduction of BPE following neoadjuvant chemotherapy correlates with the tumour response. • The classification of the BPE shows good agreement among trained readers.
OBJECTIVES: To correlate the decrease in background parenchymal enhancement (BPE) and tumour response measured with MRI in breast cancerpatients treated with neoadjuvant chemotherapy (NAC). METHODS: One hundred and forty-six MRI examinations of 73 patients with 80 biopsy-proven breast cancers who underwent breast MRI before and after NAC were retrospectively analysed. All images were reviewed by two blinded readers, who classified BPE into categories (BEC; 1 = minimal, 2 = mild, 3 = moderate, 4 = marked) before and after NAC. Histopathological and morphological tumour responses were analysed and compared. RESULTS: The distribution of BEC 1/2/3/4 was 25/46/18/11 % before and 78/20/2/0 % after NAC. On average, BPE decreased by 0.87 BEC. Cohen's kappa showed substantial agreement (k = 0.73-0.77) before and moderate agreement (k = 0.43-0.60) after NAC and moderate agreement (k = 0.62-0.60) concerning the change in BEC. Correlating the change in BPE with tumour response, the average decrease in BEC was 1.3 in cases of complete remission, 0.83 in cases with partial response, 0.85 in cases with stable disease and 0.40 in cases with progressive disease. Correlation analysis showed a significant correlation between the decrease in BEC and tumour response (r = -0.24, p = 0.03). CONCLUSIONS: BPE decreased by, on average, 0.87 BEC following NAC for breast cancer. The degree of BPE reduction seemed to correlate with tumour response. KEY POINTS: • BPE decreases by an average of 0.87 categories under neoadjuvant chemotherapy. • The reduction of BPE following neoadjuvant chemotherapy correlates with the tumour response. • The classification of the BPE shows good agreement among trained readers.
Entities:
Keywords:
Background enhancement; Breast MRI; Breast cancer; Chemotherapy; Tumour response
Authors: Valencia King; Yajia Gu; Jennifer B Kaplan; Jennifer D Brooks; Malcolm C Pike; Elizabeth A Morris Journal: Eur Radiol Date: 2012-07-04 Impact factor: 5.315
Authors: Michael J DeLeo; Susan M Domchek; Despina Kontos; Emily Conant; Jinbo Chen; Susan Weinstein Journal: AJR Am J Roentgenol Date: 2015-03 Impact factor: 3.959
Authors: Ji Youn Kim; Sung Hun Kim; Yun Ju Kim; Bong Joo Kang; Yeong Yi An; A Won Lee; Byung Joo Song; Yong Soo Park; Han Bi Lee Journal: Magn Reson Imaging Date: 2014-08-29 Impact factor: 2.546
Authors: Geraldine J Liao; Leah C Henze Bancroft; Roberta M Strigel; Rhea D Chitalia; Despina Kontos; Linda Moy; Savannah C Partridge; Habib Rahbar Journal: J Magn Reson Imaging Date: 2019-04-19 Impact factor: 4.813
Authors: John Virostko; Garrett Kuketz; Erin Higgins; Chengyue Wu; Anna G Sorace; Julie C DiCarlo; Sarah Avery; Debra Patt; Boone Goodgame; Thomas E Yankeelov Journal: Eur J Radiol Date: 2021-01-09 Impact factor: 3.528